Head-to-head evidence
Hemay007 vs infliximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
Hemay007
Developed by Tianjin Hemay Pharmaceutical
NCT02603185 · Phase 1 · status unknown
This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT04205643 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=438 randomized into maintenance phase) Phase 3 trial with a hard clinical endpoint (clinical remission by modified Mayo score) that reached statistical significance in the favorable direction, satisfying the 'strong' definition.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
Hemay007
Developed by Tianjin Hemay Pharmaceutical
NCT02603185 · Phase 1 · status unknown
This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: October 2026 · NCT05043870 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay007's landscape · infliximab's landscape